Ligelizumab for Chronic Spontaneous Urticaria
Top Cited Papers
- 3 October 2019
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 381 (14), 1321-1332
- https://doi.org/10.1056/nejmoa1900408
Abstract
In the majority of patients with chronic spontaneous urticaria, most currently available therapies do not result in complete symptom control. Ligelizumab is a next-generation high-affinity humanized monoclonal anti-IgE antibody. Data are limited regarding the dose–response relationship of ligelizumab and the efficacy and safety of ligelizumab as compared with omalizumab and placebo in patients who have moderate-to-severe chronic spontaneous urticaria that is inadequately controlled with H1-antihistamines at approved or increased doses, alone or in combination with H2-antihistamines or leukotriene-receptor antagonists.Keywords
Funding Information
- Novartis Pharma
This publication has 33 references indexed in Scilit:
- Model‐based dose finding under model uncertainty using general parametric modelsStatistics in Medicine, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaThe New England Journal of Medicine, 2013
- The role of autoimmune testing in chronic idiopathic urticariaAnnals of Allergy, Asthma & Immunology, 2012
- Clinical utility of the Chronic Urticaria IndexJournal of Allergy and Clinical Immunology, 2011
- IgE Mediated Autoallergy against Thyroid Peroxidase – A Novel Pathomechanism of Chronic Spontaneous Urticaria?PLOS ONE, 2011
- Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1Allergy, 2010
- Epidemiology of urticaria: a representative cross-sectional population surveyClinical and Experimental Dermatology, 2010
- Chronic idiopathic urticaria with functional autoantibodies: 12 years onBritish Journal of Dermatology, 2006
- Combining Multiple Comparisons and Modeling Techniques in Dose‐Response StudiesBiometrics, 2005